Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

One of the hottest growth areas in the healthcare landscape these days is the obesity drug market because of a class of drugs ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...

Combining baricitinib with narrowband UVB phototherapy led to significant repigmentation and enhanced quality of life in ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $742.35 which represents a slight increase of $16.63 or 2.29% from the prior close of $725.72. The stock opened at $731.27 and ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases like ulcerative colitis. Read the pre-IPO report here.

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Kyverna Therapeutics said it named Naji Gehchan as its chief medical and development officer. The clinical-stage biopharmaceutical company on Tuesday said that Gehchan comes from Eli Lilly, where he ...